Genzyme Jumps Into Rapidly Growing Business Of Genetic MedicinesGenzyme is spending $700 million dollars to buy a chunk of Alnylam Pharmaceuticals of Cambridge -- a much smaller company that been moving rapidly toward commercializing treatments for rare genetic diseases.

More From CBS Boston

Opioid Crisis
Download Our App
Download Weather App

Watch & Listen LIVE